Occasional review
Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma?
J M Watson, J F Cordier, K G Nicholson Influenza epidemics are regularly associated elderly. 10 Little difference has been reported in the symptoms observed in elderly people as a with excess mortality from respiratory, cardioresult of influenza or RSV infection. 11 As vascular, and cerebrovascular disease and are patients who have received influenza vacassociated with increased death rates from diacination are no less likely than those unbetes and neoplasia.
1 2 Increasing age, the presvaccinated to succumb to other respiratory tract ence of certain chronic medical conditions, infections, a proportion will inevitably contract and residence in chronic care facilities are all an infection in the week or two after imassociated with increasing morbidity and mormunisation and may attribute it to the vaccine. tality from influenza.
3-5 Many health authorities In addition, average annual influenza attack in Europe and North America recommend inrates in the community during epidemics are fluenza immunisation of children and adults estimated at 10-20%, so most patients in any with chronic respiratory disease, including one year will be unaffected. asthma, as well as a range of other conditions. 6 Concern about possible side effects of inSome also recommend immunisation of the fluenza immunisation have further reduced elderly in communal residential accomuptake rates. Precipitation of asthma or exmodation such as nursing homes where rapid acerbation of chronic airflow obstruction are spread is likely to follow the introduction of prominent among the concerns of some infection. Some countries recommend inpatients and doctors and, as a result, in Britain fluenza immunisation for all those aged over neither the British Thoracic Society nor the 65 years irrespective of their current health National Asthma Campaign have endorsed the status.
guidelines produced by the British Government Despite the guidance, uptake of influenza recommending influenza vaccination in these immunisation by those for whom it is repatient groups. 12 This brief review considers commended is low in many countries.
7 8 This the evidence that currently used inactivated may be due to doubts on the part of some influenza vaccines may cause a worsening of doctors and patients about the protective respiratory symptoms; reports relating to both efficacy of the vaccine. These doubts may asthma and chronic airflow obstruction sometimes be understandable. To be effective missions during these periods and chronic pul-manufacturer following the administration of 40 million doses. 31 monary disorders (especially asthma, chronic obstructive pulmonary disease and emSurveillance schemes for side effects associated with medicinal products, however, are physema) are the most common underlying conditions. 20 Increases in deaths from both dependent upon recognition and reporting by clinicians of conditions which might be ascardiovascular and respiratory disease contribute the largest part to the mortality during sociated with the administration of the product and considerable under-reporting occurs. Reinfluenza epidemics, 21 and deaths attributed to pneumonia and influenza are the commonest cognition of an associated side effect is made yet more difficult if the condition is very rare respiratory causes. 4 or very common.
Live influenza vaccines
  There is relatively little information available
Observational studies in patients with asthma on live attenuated influenza vaccines, although and chronic airflow obstruction have been carthere has been a report of increased bronchial ried out in a wide range of settings. The results hyperresponsiveness in a study involving 14 of these studies, which have looked at both normal subjects 22 and uncontrolled studies of pulmonary function (including bronchial rerespiratory symptoms and pulmonary function activity following methacholine challenge) and in patients with asthma and chronic airflow the occurrence of respiratory or other sympobstruction [23] [24] [25] [26] 36 reported a ume loops, revealed no adverse effects on pultrend to a decrease in peak expiratory flow rate monary function. 27 following immunisation of asthmatic children with an inactivated influenza vaccine in the late 1970s but, in a subsequent study, 37 they Inactivated influenza vaccines reported no such change in a similar group   given a different inactivated influenza vaccine. In 1992 Hassan et al reported the exacerbation Kava et al reported two studies in asthmatic of asthma after influenza immunisation in-subjects given inactivated influenza vaccine cluding three patients who had to be admitted and observed no alterations in respiratory to hospital. 28 They concluded that influenza function. 38 39 vaccine should not be offered to patients with In a study of patients with chronic airflow stable asthma. In subsequent correspondence obstruction Knowles et al 40 reported an increase Daggett 29 supported Hassan by reporting that in respiratory symptoms following inactivated he had admitted six asthmatic patients that vaccine but the study involved only 30 patients. winter who had become ill within 24 hours Other uncontrolled trials on patients with of immunisation. Subsequent correspondents chronic airflow obstruction and asthma have disagreed citing contrary evidence. 30 31 More reported no appreciable increase in the ocimportantly, these anecdotal reports were based currence of respiratory symptoms even if some on small numbers and may represent findings aspects of respiratory function were observed that occurred by chance alone.
to change. Although these observational studies have been carried out in groups of patients with asthma or chronic airflow obstruction, the ab-    Following the rapid distribution of influenza sence of controls or use of placebo, and the generally small numbers involved, make invaccine against A/New Jersey/76 to 46 million Americans in response to the outbreak of swine terpretation of the results and determination of their applicability to these groups of patients influenza at Fort Dix in 1976, surveillance for side effects from the vaccine was carried out in general very difficult. Larger observational studies have been carried out in unselected which revealed an apparent association with the Guillain-Barré syndrome. The data from groups of individuals such as the elderly 41 and hospital staff 42 43 ; a small number of local or the United States and Canada did not reveal evidence to suggest an increased occurrence of mild systemic side effects were reported in these studies but no respiratory symptoms were respiratory symptoms following vaccination. 32 33 This vaccine was monovalent, how-reported. Even in these larger studies, however, the numbers at risk of exacerbation of asthma ever, and probably not typical of most inactivated influenza vaccines. In the United or chronic airflow obstruction are likely to have been small and the significance of the mild Kingdom the Committee on Safety of Medicines received 990 reports of possible adverse systemic symptoms cannot be determined in the absence of a placebo group. reactions to influenza vaccines between 1963 and 1991; of these, only 26 were of cases of Egg allergy is a contraindication to influenza immunisation because of the traces of egg anasthma or bronchospasm. Palache and van der Velden, from one of the vaccine manufacturers, tigen contained in inactivated vaccines following their production in hens' eggs. Little reported the exceptionally low number of reports of asthma exacerbations received by the information is therefore available about the effect of vaccination in asthmatics with egg years), had an average nine year history of asthma. In the week following immunisation allergy, but one small uncontrolled trial was reported by Murphy and Strunk 44 who ad-no significant difference in the mean peak expiratory flow rate in the morning, noon or ministered an inactivated influenza vaccine to six asthmatic children with egg allergy using a evening was observed between the two groups.
Reports of dyspnoea, cough, and production low dose incremental scheme: no subsequent respiratory symptoms were observed. of sputum were "similar" (data not published) between the two groups as was the need for medication. No influence on side effects to vaccination was found when the data were    Placebo controlled trials remain the only re-analysed separately by age, sex, duration of disease, atopic status, history of attacks of liable way to answer the questions about the side effects of influenza vaccination and to asthma induced by viral infections, diurnal variation of baseline peak expiratory flow of 20% or distinguish the results observed from those that might have occurred by chance alone or those more, or patients receiving continuous steroid medication. Children and patients with egg that were the result of coincident other infections or resulted from the placebo effect of allergy or known hypersensitivity to influenza vaccines were excluded but it is not indicated the procedure rather than the vaccine product itself. In view of the infrequency with which how many subjects were considered to fall into this latter category. Patients in this study had any significant side effects to influenza immunisation occur (local soreness apart), large careful optimisation of their treatment before the study and the authors suggest that this numbers are necessary which makes the costs of a study high. To address these questions in could have improved bronchial stability and diminished the sensitivity of patients to any those with asthma or chronic airflow obstruction presents further difficulties in re-adverse effects of vaccination.
Kava et al 47 in the early 1980s investigated the cruitment and may also raise, in the view of some, insurmountable ethical issues. Con-effect of vaccine or saline placebo on respiratory functions in 27 patients with mild to moderate sequently, few such studies have been carried out. These studies have not attempted to deter-asthma. Although increased bronchial reactivity was observed in four of the 16 asthmine the protective efficacy of the vaccine against influenza related illness in the influenza matics given vaccine, it was also seen in five of the 11 asthmatic subjects who received saline. season following immunisation as rather different methodologies are required to do this. The authors concluded that natural infection or allergen exposure could not be ruled out In a randomised double blind placebo controlled crossover trial in 336 elderly people in as the cause of these results. Campbell and Edwards 48 gave both inactivated trivalent inthe 1988/89 influenza season Margolis et al 45 reported no significant difference between in-fluenza vaccine and saline placebo to 28 asthmatic subjects in a crossover study conducted activated trivalent split antigen influenza vaccine and saline placebo with respect to the over three weeks. Both respiratory symptoms and peak expiratory flow rate were recorded. proportion of subjects reporting disability or systemic symptoms. Although 13.2% of sub-A mean reduction in evening peak expiratory flow of 168 l/min was observed during the week jects reported coryzal symptoms in the week following immunisation and 6.6% cough, the after vaccination which just reached statistical significance, but no change in symptoms occorresponding figures in those who received placebo were 10.2% and 5.1%, respectively curred. Neither of these studies was large enough to provide results that could be reliably (p=0.27 and 0.62). Non-specific symptoms of feverishness, fatigue, malaise, myalgia, head-extended to the asthmatic population in general. ache, and nausea were reported by between 4.5% and 8.0% of vaccinated subjects which Govaert et al 49 randomised 1806 elderly people in 1991 to receive inactivated influenza was not significantly more frequent than in those who had received placebo. However, vaccine or placebo in a double blind study.
Patients living in residential accommodation 20.1% of vaccinated subjects reported a sore arm compared with 4.9% of those who received were excluded. The vaccine and placebo groups were similar with respect to age, sex, previous placebo (p<0.001). No information is provided about the number of subjects with asthma or vaccination, and risk status (including heart and lung conditions and diabetes mellitus). chronic airflow obstruction although two thirds of the subjects, who were randomly sampled Adverse reactions were reported on a postal questionnaire completed four weeks after vacfrom ambulatory outpatients of a Veterans hospital, were reported to have "chronic illness that cination. About 11% of both the vaccine and placebo group had underlying chronic pulwould predispose them to increased influenza morbidity". The authors acknowledged that monary disease, including 179 with asthma, chronic airflow obstruction and/or brontheir results, derived in an exclusively elderly population, may not be generally applicable to chiectasis (ThME Govaert, personal communication). Overall, 23.2% of patients who young adults or children.
Stenius-Aarniala et al conducted a study in received the vaccine reported side effects compared with 14.1% who received placebo (p= 1981 of 318 adults with chronic asthma in Finland. Subjects were randomised to receive 0.82). Local reactions at the site of the vaccination such as swelling, itching and pain were inactivated split bivalent influenza vaccine or saline placebo. 46 The subjects, who ranged in significantly more common in the vaccinated group (17.5% versus 7.3%, p<0.001). Systemic age between 20 and 73 years (mean 47-48 reactions such as fever, headache, or malaise reported in vaccine recipients than in subjects receiving saline placebo, but no significant inwere no more common, however, in the vaccinated group than in the controls (11% versus crease in systemic or respiratory symptoms has been reported following influenza vaccination. 9.4%, p=0.34). The occurrence of respiratory symptoms was not specifically sought in this However, the number of asthmatic subjects in even the largest of the studies was small. If a study although one subject who had received placebo reported mild dyspnoea (ThME Go-side effect was observed in 5% of subjects receiving placebo, 474 subjects in both the vaert, personal communication). Women reported more side effects than men although vaccine and placebo groups would be needed to detect, with 80% power, a statistically sigfever, the only adverse reaction studied that could be measured objectively, was reported nificant effect in 10% or more of the vaccinated group. Even with study numbers this large a by similar numbers of men and women. This study provided no information about the like-side effect which occurred in nearly twice the proportion of vaccinated subjects than controls lihood of side effects in younger adults and children, but did find a suggestion that side might not be detected.
The currently available information provides effects became less likely with increasing age. The authors felt that this finding may have no evidence that exacerbation of these conditions following administration of inactivated been biased by the fact that there were many fewer patients in the older age groups. Previous influenza vaccines occurs more often than by chance alone. However, further studies are vaccination status made no difference to the likelihood of adverse reactions.
needed. The number of placebo controlled trials on inactivated influenza vaccine is small, the number of subjects in some of the trials is very small, and the amount of data relating Conclusions Influenza vaccine is usually given at the time to the occurrence of respiratory symptoms in patients with asthma or chronic airflow obof year when the number of respiratory virus infections in the community is beginning to struction is limited. Future studies should be randomised, double blind, and placebo conincrease and a certain proportion of patients would be expected to experience such in-trolled, they should recruit subjects of all ages with asthma or chronic airflow obstruction, and fections after immunisation by chance alone. It is not surprising, therefore, that anecdotal should be large enough to demonstrate real effects if they exist. Follow up should include experience dominates individual clinician and patient attitudes to the vaccine. In addition, in both objective measures of pulmonary function such as spirometric tests as well as the ocsome years the protection offered by the vaccine may be limited as a result of a poor match currence of respiratory symptoms. The positive results of recent major case control studies on between the vaccine and circulating influenza viruses. This limitation to the effectiveness of the protective effect of influenza immunisation in the elderly 9 are likely to influence the decision the vaccine, and the fact that influenza epidemics generally affect only a minority of of some clinicians to vaccinate their patients.
Only conclusive evidence from one or more patients in any one year, may influence the relative importance that clinicians attach to well conducted studies of the side effects of the vaccine will persuade some sceptical clinicians the potential side effects of influenza immunisation.
caring for anxious patients with respiratory disease that the risk of side effects from the vaccine The currently available evidence indicates that respiratory viral infections may precipitate is outweighed by the risk of influenza itself.
The weight of the current evidence, however, asthma or cause exacerbation of chronic airflow obstruction. Some live influenza virus vaccines supports the majority of clinicians who continue to follow the recommendations of authors have been associated with lower respiratory tract symptoms and pulmonary function ab-in both Britain and the United States greater proportion of local reactions has been
